Introduction {#s1}
============

Chikungunya virus (CHIKV) is an arthropod-borne virus that belongs to the *Alphavirus* genus. Chikungunya disease is characterized by polyarthralgia, sometimes associated with rash. The articular symptoms, often debilitating, usually resolve within weeks, but have been reported to last for months, even though the natural history of this infection has not been precisely studied in prospective studies [@pntd.0002137-Brighton1], [@pntd.0002137-Calabrese1], [@pntd.0002137-DupuisMaguiraga1].

In 2005, CHIKV emerged in islands of Indian Ocean including La Réunion, a French overseas department, and approximately one third of the inhabitants (*i.e.* ∼300,000) was infected at the end of the outbreak in 2006 [@pntd.0002137-Enserink1], [@pntd.0002137-Gerardin1]. Compared to earlier outbreaks, this episode occurred in a highly medicalized area. Moreover previously unreported severe forms of Chikungunya were observed, such as encephalopathy [@pntd.0002137-Lemant1], [@pntd.0002137-Schuffenecker1], and mother-to-child CHIKV transmission was demonstrated, leading to severe neonatal CHIKV infection [@pntd.0002137-Gerardin1]. In the wake of this outbreak, CHIKV also re-emerged in India with over 1 million cases [@pntd.0002137-Burt1], [@pntd.0002137-Mavalankar1]. In 2007, CHIKV emerged for the first time in Europe, causing an outbreak in Italy [@pntd.0002137-Rezza1].

We have described the clinical and biological features of acute CHIKV infection in a prospective cohort of patients with positive blood CHIKV RT-PCR [@pntd.0002137-Staikowsky1]. It included all patients referred to the Emergency Department in Saint-Pierre de la Réunion with febrile arthralgia between March and May 2006. As little is known about long-term outcome of CHIKV infection, we conducted a prospective longitudinal study to describe in details the specific clinical and biological features of chronic arthralgia, as well as clinical signs associated to this pathology. We evaluated the consequences of long-term arthralgia on patients\' daily and social life, looked for risk factors associated with them and estimated their economic impact.

Materials and Methods {#s2}
=====================

Ethics & STROBE statement {#s2a}
-------------------------

Ethical clearance was obtained from the «Comité de Protection des Personnes Sud-Ouest et Outre-Mer III» of Saint-Pierre, La Réunion, Paris (CCP 2008/65, n° 2008-A00999-46). CHIK-IMMUNOPATH received approval from the ethical committee for studies with human subjects (CPP) of Bordeaux and the National Commission for Informatics and Liberty (CNIL). Written informed consent was obtained from patients included in the CHIK-IMMUNOPATH study. The study respects the STROBE statement ([supporting information S1](#pntd.0002137.s001){ref-type="supplementary-material"}).

Patients {#s2b}
--------

We studied a cohort of patients (n = 180) enrolled for febrile arthralgia to the Emergency Department of the Groupe Hospitalier Sud Réunion between March 2005 and May 2006 [@pntd.0002137-Staikowsky1]. Patients were interviewed by telephone 4, 6, 14 and 36 months (M4, M6, M14 and M36) after the viremic phase, using the same questionnaire as that used at day 0 (D0) ([supporting information S2](#pntd.0002137.s002){ref-type="supplementary-material"}). At M36 after the acute phase, all patients who agreed to participate to a complementary study (CHIK-IMMUNOPATH) and who were arthralgic were interviewed and underwent clinical examination. Among them, 22 patients with arthralgia (ART+) and 20 patients without persisting arthralgia (ART−) were randomly selected from the cohort. They signed a written consent and a blood sample was collected.

Laboratory tests performed at M36 {#s2c}
---------------------------------

Blood cell count was performed and viremia was tested by qRT-PCR [@pntd.0002137-Grivard1]. Both serum anti-CHIKV IgG and IgM specific antibodies were screened. An enzyme-linked immunosorbent assay (ELISA) was performed with CHIKV antigen [@pntd.0002137-Grivard1]. The avidity of anti-CHIKV IgG was tested by ELISA in the presence or absence of urea 8 M [@pntd.0002137-Matheus1]. Geometric Mean Antibody Titer (GMAT) was calculated as previously described [@pntd.0002137-Julvez1].

Plasmatic protein electrophoresis was performed and C-reactive protein (CRP) concentration was measured. The presence of anti-nuclear, anti-dsDNA, anti-endomysium autoantibodies, anti-cyclic citrullinated peptide antibody (ACCP) and cryoglobulinemia were investigated. Samples were transported at 37°C to research cryoglobulins. Sera were sent to Myriad RBM (Austin,Texas) and analyzed by Luminex using the inflammation MAP. Assays are run according to CLIA guidelines and in all cases, \>100 beads per analyte were measured with CV \<10% for values that are above the limit of quantification for the given assay.

Statistical analysis {#s2d}
--------------------

For each time point, the proportion of patients with monoarthralgia (1 site), oligoarthralgia (2--3 sites) or polyarthralgia (4 sites or more) were compared using a Chi-2 test.

A logistic regression model was used to identify factors associated with long-term arthralgia, defined as presence of arthralgia at M14. We studied factors at D0, including demographic factors (gender and age), biological markers, hospitalization and comorbidities, and factors measured at M4 (arthralgia, treatment, and quality of life). All factors associated with long-term arthralgia with a p-value\<0.15 in univariate analysis were entered in the multivariate model. A step-by-step backward procedure was then used to identify factors significantly associated with long-term arthralgia. A sensitivity analysis was also conducted, following the same procedure, defining long-term persistence of arthralgia as the presence of arthralgia at M36. To address the lost of follow up at M36, we looked for parameters that differentiate the patients who were lost between M14 and M36 and these who were followed.

Statistical analyses were performed using the STATA software (Stata Corporation, College Station, Texas, USA); all significance tests were two-sided and p-values\<0.05 were considered significant. Luminex data were mined using the Omniwiz software (Biowisdom) and Mann-Whitney analysis is reported. False discovery rate (FDR or *q-*values) were calculated as correction for multiple analyte testing.

To characterize the spatiotemporal evolution of arthralgia, we considered different types of arthralgia. For a given site at a given time point, arthralgia was defined either as a "persistent symptom" if the affected site was the same as that reported during the previous time point, as "a relapse of an the acute symptom" if the site affected was the same as that at the acute phase, or as "a new symptom" if this site was not affected at the acute phase, or as a "migrating symptom" if the arthralgia was localized at a site distinct from that previously reported. For a given patient, these categories were not mutually exclusive. For modeling migratory arthralgia, we divided joints into three groups: upper limb joints (hand, wrist, elbow), mid body joints, (shoulder, spine, hip) and lower limb joints (foot, ankle, knee), and considered two migratory probabilities for migration to sites within to the same group (e.g., hand to wrist) or to a different group (e.g., hand to foot) ([Supporting information S3](#pntd.0002137.s003){ref-type="supplementary-material"} and [Table S1](#pntd.0002137.s004){ref-type="supplementary-material"}).

Results {#s3}
=======

Characteristics of long-term arthralgia in CHIKV-infected patients {#s3a}
------------------------------------------------------------------

At M4, M6, M14 and M36 after their inclusion as acute CHIKV-infected patients, all patients were interviewed using a questionnaire to monitor persistence of arthralgia, other clinical signs and treatments. The number of patients that participated is provided in [Figure 1](#pntd-0002137-g001){ref-type="fig"}. There is an important lost of follow up between M14 and M36 however we did not identify a bias associated with it. Among the 180 patients, 76 patients were followed at all time points of the study.

![Diagram of the clinical study.\
"unable": patients who were reached but unable to answer to the questionnaire, "lost": patient lost of follow up until the end of the study, "temporally lost": not reached at a specific timepoint, "death": dead patients.](pntd.0002137.g001){#pntd-0002137-g001}

The percentage of patients suffering from long-term arthralgia decreased after CHIKV acute infection and stabilized around 60% ([Figure 2A](#pntd-0002137-g002){ref-type="fig"}). Of note, all patients suffered from arthralgia at D0. Among them, only 5 on 180 (2.8%) suffered from joint pain prior to CHIKV infection.

![Evolution and characterization of arthralgia in CHIKV patients.\
(A) Percentage of patients with arthralgia among participating patients, (B) localization of arthralgia among patients with arthralgia, (C) number of arthralgia sites among the 76 patients answering at every time point and having arthralgia, (D) complete model presenting the probability for one joint to be painful depending on its previous state.](pntd.0002137.g002){#pntd-0002137-g002}

Most patients had intermittent arthralgia, with recovery and relapse. For each time point, 25 to 40% of patients complained of permanent arthralgia. Among the 76 patients that could be followed at each time point, 45% had arthralgia at all time, 24% experienced partial recovery at M4, M6 or M14 then relapses, and 31% fully recovered from acute symptoms. Among patients who experienced chronic symptoms at M36, 43.5% reported arthralgia triggered by a change in ambient temperature, 8% by physical effort. At M36, arthralgia caused stiffness in 75.5% of patients with symptoms, and 67.7% of the patients reported a need of morning stretching (time of 32 minutes, standard deviation (SD) 37 minutes, range 5--180 minutes).

We monitored arthralgia in 9 anatomical sites ([Figure 2B](#pntd-0002137-g002){ref-type="fig"}). Arthralgia in upper limbs mostly affected fingers and wrists, while lower limbs arthralgia mostly affected knees and ankles. At each time point, these locations remain significantly the most affected (Mac Nemar test for matched pairs of subjects). Importantly, arthralgia were typically symmetrical (90%).

We then investigated whether the number of arthralgic sites diminished in patients still suffering from arthralgia among the 76 patients followed at all time points. The number of arthralgia sites decreased until M14, with only 30% of patients suffering from polyarthralgia (number of arthralgia sites \>2) ([Figure 2C](#pntd-0002137-g002){ref-type="fig"}). Despite an increase of arthralgic sites at M36, there is an overall significant decrease of the number of painful joints during the study period (p\<0.01).

We attempted to model the spatiotemporal evolution of arthralgia, as defined in the [Materials and Methods](#s2){ref-type="sec"} section. We found that "persistent" symptoms had the strongest effect, as its probability of occurrence was three times higher than a "new" symptom ([Figure 2D](#pntd-0002137-g002){ref-type="fig"}). The probability of relapse of an "acute" symptom was twice the appearance of a "new" symptom. Finally, "migratory" symptoms tended to be intra-group as compared to inter-group migrations.

Other clinical signs associated with CHIKV chronic disease and their consequences {#s3b}
---------------------------------------------------------------------------------

Patients with arthralgia at M36 showed other clinical symptoms, including local swelling, cutaneous symptoms, myalgia and osteoligamentaous pain ([Table 1](#pntd-0002137-t001){ref-type="table"}). Local swelling localized to affected joints for 63% of patients. Moreover, sleep, memory or concentration disorders and asthenia or depression are significantly associated with arthralgic patients.

10.1371/journal.pntd.0002137.t001

###### Clinical signs and treatment in arthralgic and non-arthralgic patients 36 months after the acute phase.

![](pntd.0002137.t001){#pntd-0002137-t001-1}

                                           Patients with arthralgia (n = 62)   Patients w/o arthralgia (n = 33)   Chi-2 test[§](#nt101){ref-type="table-fn"}
  --------------------------------------- ----------------------------------- ---------------------------------- --------------------------------------------
  **Clinical signs**                                                                                             
  Local swelling                                      39 (62.9%)                            0 (0%)                  [\*\*\*](#nt103){ref-type="table-fn"}
  Osteo-ligamentous pain                              22 (35.5%)                            0 (0%)                  [\*\*\*](#nt103){ref-type="table-fn"}
  Myalgia                                             24 (38.7%)                            0 (0%)                  [\*\*\*](#nt103){ref-type="table-fn"}
  Cutaneous lesion                                    31 (50.0%)                          5 (15.1%)                 [\*\*\*](#nt103){ref-type="table-fn"}
  Asthenia                                            48 (77.4%)                          7 (21.2%)                 [\*\*\*](#nt103){ref-type="table-fn"}
  Sleeping disorder                                   35 (56.4%)                           3 (9.1%)                 [\*\*\*](#nt103){ref-type="table-fn"}
  Dysgeusia                                           11 (17.7%)                           3 (9.1%)                                   NS
  Depression                                          31 (50.0%)                            2 (6%)                  [\*\*\*](#nt103){ref-type="table-fn"}
  Memory disorder                                     27 (43.5%)                            2 (6%)                  [\*\*\*](#nt103){ref-type="table-fn"}
  Concentration disorder                              24 (38.7%)                            2 (6%)                  [\*\*\*](#nt103){ref-type="table-fn"}
  **Treatment**                                                                                                  
  Followed by a general practioner                    50 (80.6%)                            1 (3%)                  [\*\*\*](#nt103){ref-type="table-fn"}
  Treatment                                           51 (82.2%)                            0 (0%)                  [\*\*\*](#nt103){ref-type="table-fn"}
  Continous treatment                                  25 (49%)                             0 (0%)                  [\*\*\*](#nt103){ref-type="table-fn"}
  Paracetamol                                         45 (72.5%)                            0 (0%)                  [\*\*\*](#nt103){ref-type="table-fn"}
  Morphinic                                             0 (0%)                              0 (0%)               
  Non-steroidal anti-inflammatory drugs               12 (23.5%)                            0 (0%)                   [\*\*](#nt102){ref-type="table-fn"}
  Corticosteroids                                      3 (5.9%)                             0 (0%)                                    NS

ns: Non significant.

p\<0.01.

p\<0.001.

The proportion of patients with arthralgia who attended a physician or received a treatment significantly increased between M4 and M36 (p = 0.01) (data not shown), and reached 80% ([Table 1](#pntd-0002137-t001){ref-type="table"}). Similarly, the number of patients receiving a treatment increased and these treatments are statistically associated with the arthralgic status of the patient (p\<0.001).

Arthralgia in patients at M36 were highly incapacitating for daily life tasks, professional life and spare-time activities ([Table 2](#pntd-0002137-t002){ref-type="table"}).

10.1371/journal.pntd.0002137.t002

###### Impact of arthralgia on daily life for patients at M36.

![](pntd.0002137.t002){#pntd-0002137-t002-2}

                                        Arthralgic patients (n = 62)   Non arthralagic patients (n = 33)   Chi-2 test[§](#nt104){ref-type="table-fn"}
  ------------------------------------ ------------------------------ ----------------------------------- --------------------------------------------
  **Impact on quality of life**                                                                           
  rising from a chair                            39 (48.4%)                         0 (0%)                                 **\*\*\***
  walking                                        34 (54.8%)                         0 (0%)                                 **\*\*\***
  picking up an object                           34 (54.8%)                         0 (0%)                                 **\*\*\***
  opening a bottle                               33 (53.2%)                         0 (0%)                                 **\*\*\***
  drinking glass                                 26 (41.9%)                         0 (0%)                                 **\*\*\***
  to wash oneself                                23 (37.1%)                         0 (0%)                                 **\*\*\***
  At least one of these disabilities             48 (77.4%)                         0 (0%)                                 **\*\*\***
  **Impact on working life**                                                                              
  With activity                                  15 (24.2%)                       17 (51.5%)              
  No impact                                       3 (20%)                         16 (94.1%)                               **\*\*\***
  Physical impact                                 12 (80%)                         1 (5.9%)               
   low impact                                    7 (46.7%)                         1 (5.9%)               
   moderate impact                                3 (20%)                           0 (0%)                
   high impact                                   2 (13.3%)                          0 (0%)                
  **Impact on leisure-time**                                                                              
  No impact                                      13 (39.4%)                       31 (93.9%)              
  Physical impact                                 49 (79%)                         2 (6.1%)                                **\*\*\***
  low impact                                     8 (24.2%)                          1 (3%)                
  moderate impact                                18 (54.5%)                         0 (0%)                
  high impact                                    23 (69.7%)                         1 (3%)                

\*\*p\<0.01. \*\*\*p\<0.001.

Identification of risk factors for developing long-term CHIKV-associated arthralgia {#s3c}
-----------------------------------------------------------------------------------

To identify risk factors associated with long-term arthralgia, we performed univariate and multivariate statistical analyses at M14, as the participation was higher than at M36 ([Table 3](#pntd-0002137-t003){ref-type="table"}). Gender was not associated with long-term arthralgia, age less than 35 years was protective. Risk of arthralgia was not associated with indicators of the disease severity during the acute phase (viral load, duration of hospitalization or number of sites of arthralgia at D0) [@pntd.0002137-Staikowsky1], however it was weakly associated with C-reactive protein (CRP) level at D0. Diabetes was the only comorbidity found to be a risk factor for long-term arthralgia. Interestingly, arthralgia at M14 was strongly associated with arthralgia at M4, and even more if arthralgia was permanent at M4. Memory and concentration disorders at M4 were also identified as risk factors for developing long-term arthralgia. Arthralgia, memory disorders and concentration disorders at M4 were the only risk factors significantly and independently associated with long-term arthralgia. When long-term arthralgia was assessed at M36, results were very similar.

10.1371/journal.pntd.0002137.t003

###### Identification of risk factors for persistence of arthralgia 14 months after CHIKV acute disease (univariate analysis).

![](pntd.0002137.t003){#pntd-0002137-t003-3}

                                            Patients at M14 N   Patients with arthralgia N (%)   Odd Ratio (95% CI[§](#nt105){ref-type="table-fn"})        p
  ---------------------------------------- ------------------- -------------------------------- ---------------------------------------------------- -------------
  Gender                                                                                                                                             
  Male                                             73                     41 (56.2%)                             0.78 (0.40--1.51)                       0.46
  Female                                           74                     46 (62.2%)                                     1                           
  Age (years)                                                                                                                                        
  ≤35                                              30                     9 (30.0%)                              0.18 (0.05--0.57)                     **0.005**
  36--50                                           28                     19 (67.9%)                             0.87 (0.26--2.84)                   
  51--60                                           24                     17 (70.8%)                                     1                           
  61--70                                           20                     15 (75.0%)                             1.24 (0.32--4.73)                   
  \>70                                             45                     27 (60.0%)                             0.62 (0.21--1.79)                   
  Hospitalization at D0                                                                                                                              
  No                                               101                    61 (60.4)                                      1                               0.66
  Yes                                              46                     26 (56.5)                              0.85 (0.42--1.73)                   
  Viral quantification at D0 (copies/mL)                                                                                                             
  ≤100.000                                         70                     39 (55.7)                                      1                               0.41
  \>100.000                                        77                     48 (62.3)                              1.32 (0.68--2.54)                   
  CRP at D0 (unit)                                                                                                                                   
  \<10                                             20                      7 (35.0)                                      1                             **0.02**
  \>10                                             126                    79 (62.7)                              3.12 (1.16--8.38)                   
  Missing                                           1                     1 (100.0)                                 No estimable                     
  Diabetes at D0                                                                                                                                     
  No                                               109                    58 (53.2)                                      1                             **0.01**
  Yes                                              38                     29 (76.3)                              2.83 (1.23--6.54)                   
  Arthralgia at M4                                                                                                                                   
  No                                               26                      5 (19.2)                            **0.10 (0.04--0.30)**                  **\<0.001**
  Yes                                              99                     69 (60.7)                                      1                           
  Missing                                          22                     13 (59.1)                              0.63 (0.24--1.62)                   
  Arthralgia at M4                                                                                                                                   
  No                                               26                      5 (19.2)                            **0.25 (0.08--0.78)**                  **\<0.001**
  Yes. intermittent                                43                     21 (48.8)                                      1                           
  Yes. permanent                                   56                     48 (85.7)                            **6.28 (2.41--16.38)**                
  Missing                                          22                     13 (59.1)                              1.51 (0.53--4.28)                   
  Memory disorder at M4                                                                                                                              
  No                                               87                     41 (47.1)                                      1                            **\<0.001**
  Yes                                              38                     33 (86.8)                            **7.40 (2.64--20.75)**                
  Missing                                          22                     13 (59.1)                              1.62 (0.63--4.18)                   
  Concentration disorder at M4                                                                                                                       
  No                                               94                     45 (47.9)                                      1                            **\<0.001**
  Yes                                              31                     29 (93.6)                           **15.79 (3.56--69.97)**                
  Missing                                          22                     13 (59.1)                              1.57 (0.61--4.03)                   

confidence interval.

Arthralgia status, systemic inflammation and autoimmunity markers {#s3d}
-----------------------------------------------------------------

At M36, 22 patients with arthralgia (ART+) and 20 patients without arthralgia (ART−) were randomly selected from the cohort to participate to the CHIK IMMUNOPATH study. Its aim was to titrate anti-CHIKV antibodies and identify a serum inflammatory or autoimmune signature associated with the arthralgia phenotype.

All patients were negative for CHIKV RT-PCR, and exhibited anti-CHIKV IgGs in serum, while a minority (9.5%) harbored measurable levels of anti-CHIKV IgM. The activity of CHIKV IgG (GMAT) was significantly higher in ART+ patients (30) than in ART− patients (20), but antibody avidity was comparable in both groups (mean ±SD: 31,6±20,4 in ART + patients and 33,7±19,8 in ART− patients). Although lymphopenia is a defining feature of acute CHIKV disease [@pntd.0002137-Staikowsky1], it was a rare finding at M36 (data not shown). Plasma protein levels measured by electrophoresis and CRP concentration were within normal ranges. However, CRP levels were significantly higher in the ART+ group than in the ART− group (mean ±SD: 3.35±3.00 mg/ml and 1.85±2.49 mg/ml, respectively; p = 0.04).

We used Luminex xMAP technology to assay analytes in the serum of patients. Most analytes were undetectable in both groups of patients ([Table 4](#pntd-0002137-t004){ref-type="table"}). Five inflammation markers were significantly elevated in ART+ patients: factor VII, C3 complement component, IL1α, IL15 and CRP ([Figure 3](#pntd-0002137-g003){ref-type="fig"}). Ferritin level was significantly lower in ART+ patients than in ART− patients. These markers did not allow for the identification of a subgroup within the ART+ group, nor did they correlate one with another. No autoimmune marker and no anti-DNA antibody in the serum of ART+ patients were detected, although anti-nuclear antibodies were detected at low level in four ART+ patients. Three patients had elevated anti-nuclear antibodies, one in the ART+ group and two in the ART- group.

![Distinctive markers in serum of patients with arthralgia (ART+ in black) versus patients without arthralgia (ART−, in white) at M36.\
SD: standard deviation, results of Mann Whitney test are shown. \* p\<0.05, q = 0.056.](pntd.0002137.g003){#pntd-0002137-g003}

10.1371/journal.pntd.0002137.t004

###### Analytes titrated in arthralgic and non arthralgic patients 36 months after the acute phase.

![](pntd.0002137.t004){#pntd-0002137-t004-4}

                                                                            Arthalgia (n = 20 patients)   No Arthalgia (n = 22 patients)   Statistic                                                       
  ----------------------------------------------------- --------- -------- ----------------------------- -------------------------------- ----------- ------- ------- -------- -------- -------- --------- ---------
  IP-10                                                   pg/mL     116                 18                             170                    214       376     20      126      207      379      0.537     0.606
  Alpha-2-Macroglobulin A2Macro                           mg/mL    0.472                18                             0.6                    0.7       0.9     21      0.7      0.8      1.1      0.194     0.434
  Alpha-1-Antitrypsin AAT                                 mg/mL     1.33                20                             1.9                    2.1       2.6     22      1.8      2.0      2.1      0.305     0.606
  Beta-2-Microglobulin B2M                                ug/mL    0.914                20                             1.1                    1.4       1.9     22      1.2      1.3      1.6      0.481     0.606
  Brain-Derived Neurotrophic Factor BDNF                  ng/mL     4.7                 20                              12                    17        24      22       14       18       21      0.940     0.966
  Complement C3 C3                                        mg/mL     0.93                20                             1.4                    1.5       1.8     22      1.0      1.2      1.5      0.029     0.056
  C-Reactive Protein CRP                                  ug/mL    0.063                20                             1.5                    2.8       5.8     22      0.5      1.3      2.4      0.035     0.056
  Eotaxin-1                                               pg/mL     70.8                20                             165                    195       290     22      154      238      329      0.705     0.920
  Factor VII                                              ng/mL     142                 20                             443                    529       632     22      324      383      561      0.020     0.056
  Fibrinogen                                              ug/mL     0.93                20                             1.6                    1.9       2.4     22      1.4      2.0      2.4      0.950     0.966
  Ferritin FRTN                                           ng/mL     14.7                20                              34                    112       156     22       68      159      273      0.034     0.056
  *Granulocyte-Macrophage Colony-Stimulating Factor*     *pg/mL*    *0*                 *0*                           *0.0*                  *0.0*     *0.0*    *0*    *0.0*    *0.0*    *0.0*     *NA*      *NA*
  Haptoglobin                                             mg/mL    0.007                20                             1.0                    1.6       2.1     21      0.6      0.9      1.8      0.194     0.434
  Intercellular Adhesion Molecule 1 ICAM-1                ng/mL     32.1                20                              88                    98        119     22       87      107      121      0.801     0.920
  *Interferon gamma IFN-gamma*                           *pg/mL*   *0.9*                *6*                           *0.9*                  *0.9*     *0.9*    *2*    *0.9*    *0.9*    *1.0*    *0.038*   *0.056*
  *Interleukin-1 alpha IL-1 alpha*                       *pg/mL*   *1.51*               *2*                           *1.4*                  *1.4*     *3.1*   *10*    *1.4*    *1.4*    *1.4*    *0.007*   *0.010*
  *Interleukin-1 beta IL-1 beta*                         *pg/mL*   *2.68*               *0*                           *2.4*                  *2.4*     *2.4*    *2*    *2.4*    *2.4*    *2.4*    *0.091*   *0.112*
  Interleukin-10 IL-10                                    pg/mL     1.55                17                             1.6                    2.2       2.8     18      1.6      2.2      2.6      0.808     0.920
  *Interleukin-12 Subunit p40 IL-12p40*                  *ng/mL*    *0*                 *0*                           *0.0*                  *0.0*     *0.0*    *0*    *0.0*    *0.0*    *0.0*     *NA*      *NA*
  *Interleukin-12 Subunit p70 IL-12p70*                  *pg/mL*   *29.3*               *0*                            *29*                  *29*      *29*     *3*     *29*     *29*     *29*    *0.051*   *0.056*
  *Interleukin-15 IL-15*                                 *ng/mL*   *0.2*                *5*                           *0.2*                  *0.2*     *0.4*   *11*    *0.2*    *0.2*    *0.2*    *0.021*   *0.056*
  *Interleukin-17 IL-17*                                 *pg/mL*   *0.9*                *9*                           *0.9*                  *0.9*     *1.5*   *11*    *0.9*    *0.9*    *1.5*    *0.838*   *0.920*
  Interleukin-18 IL-18                                    pg/mL     61.3                20                             117                    135       235     22      130      153      189      0.811     0.920
  Interleukin-1 receptor antagonist IL-1ra                pg/mL     50.2                15                              87                    113       154     22       49       87      129      0.090     0.112
  *Interleukin-2 IL-2*                                   *pg/mL*   *2.8*                *0*                           *2.8*                  *2.8*     *2.8*    *2*    *2.8*    *2.8*    *2.8*    *0.573*   *0.606*
  *Interleukin-23 IL-23*                                 *ng/mL*   *0.4*                *8*                           *0.4*                  *0.4*     *0.7*    *8*    *0.4*    *0.4*    *0.7*    *0.787*   *0.920*
  *Interleukin-3 IL-3*                                   *pg/mL*   *5.1*                *1*                           *5.1*                  *5.1*     *5.1*   *0.0*   *5.1*    *5.1*    *5.1*     *NA*      *NA*
  *Interleukin-4 IL-4*                                   *pg/mL*   *2.6*                *1*                           *2.6*                  *2.6*     *2.6*    *5*    *2.6*    *2.6*    *2.6*    *0.111*   *0.112*
  Interleukin-5 IL-5                                      pg/mL     3.8                 11                             3.8                    4.8       6.8     16      3.4      3.8      5.1      0.168     0.406
  *Interleukin-6 IL-6*                                   *pg/mL*   *5.8*                *1*                           *5.8*                  *5.8*     *5.8*    *0*    *5.8*    *5.8*    *5.8*    *0.133*   *0.352*
  *Interleukin-7 IL-7*                                   *pg/mL*    *5*                 *4*                           *5.0*                  *5.0*     *5.0*    *1*    *5.0*    *5.0*    *5.0*    *0.112*   *0.112*
  Interleukin-8 IL-8                                      pg/mL     2.8                 19                              9                     17        46      20       9        11       24      0.650     0.897
  Monocyte Chemotactic Protein 1 MCP-1                    pg/mL     33.7                20                             105                    170       216     22      129      150      172      0.435     0.606
  Macrophage Inflammatory Protein-1 alpha MIP-1 alpha     pg/mL     10.6                15                              11                    16        46      16       11       27       36      0.869     0.933
  Macrophage Inflammatory Protein-1 beta MIP-1 beta       pg/mL     112                 20                             194                    284       431     22      242      269      328      0.950     0.966
  *Matrix Metalloproteinase-2 MMP-2*                     *ng/mL*    *0*                 *0*                           *0.0*                  *0.0*     *0.0*    *0*    *0.0*    *0.0*    *0.0*     *NA*      *NA*
  Matrix Metalloproteinase-3 MMP-3                        ng/mL     2.31                20                             2.9                    5.7       8.8     22      5.5      6.9      10.3     0.162     0.406
  Matrix Metalloproteinase-9 MMP-9                        ng/mL     1.3                 12                             1.2                    1.3       1.3     15      1.2      1.3      1.3      0.305     0.606
  T-Cell-Specific Protein RANTES RANTES                   ng/mL     3.81                20                              7                     16        21      22       9        17       23      0.345     0.606
  Stem Cell Factor SCF                                    pg/mL     60.4                20                             155                    192       229     22      140      167      219      0.239     0.514
  Tissue Inhibitor of Metalloproteinases 1 TIMP-1         ng/mL     68.7                20                             120                    132       169     22      126      144      177      0.623     0.897
  Tumor Necrosis Factor alpha TNF-alpha                   pg/mL     1.33                20                             2.0                    2.2       2.7     21      1.8      2.2      2.7      0.643     0.897
  *Tumor Necrosis Factor beta TNF-beta*                  *pg/mL*   *12.1*               *1*                            *12*                  *12*      *12*     *1*    *12.1*   *12.1*   *12.1*   *0.612*   *0.897*
  Tumor Necrosis Factor Receptor-Like 2 TNFR2             ng/mL     2.51                20                              3                      4         8      22      3.3      4.0      5.2      0.364     0.606
  Vascular Cell Adhesion Molecule-1 VCAM-1                ng/mL     323                 20                             460                    595       707     22      490      539      640      0.606     0.606
  Vitamin D-Binding Protein VDBP                          ug/mL     114                 20                             158                    273       372     22      237      259      303      0.762     0.920
  Vascular Endothelial Growth Factor VEGF                 pg/mL     288                 20                             458                    628       763     22      492      579      786      0.811     0.920
  von Willebrand Factor vWF                               ug/mL     13.7                20                              21                    28        35      22       20       26       34      0.762     0.920

DET: number of patients with detectable value within the group.

MED: 25%; 75%:median and interquartile.

LOD: lowest limit of detection.

M-W PV: Mann Whithney P value.

M-W FDR Mann Whitney with False Discovery Rate Correction.

As it has been reported that CHIKV could evolve into rheumatoid arthritis [@pntd.0002137-Bouquillard1], we screened for cyclic citrullinated protein antibodies. We also assayed for cryoglobulinemia and anti-endomysium IgA antibodies. All patient were found to be negative.

Estimation of the economic impact of CHIKV long-term arthralgia {#s3e}
---------------------------------------------------------------

We estimated the annual economic burden of long-term arthralgia by taking into account the cost of medical visits, therapeutic treatment and the cost for lost work time due to injury or pain (using the population of La Réunion Island as a reference) ([Table S2](#pntd.0002137.s005){ref-type="supplementary-material"}). We found that arthralgia secondary to the CHIKV outbreak in La Réunion in 2005-06 has resulted so far in an estimated total cost of up to 34 millions euros per year. This corresponds to 250€ per year and per patient with long-term arthralgia. However, it should be noted that this sum might be overestimated due to the bias in our cohort selection, as our cohort is likely composed of the most severely affected patients who were referred to the hospital during the acute phase.

Discussion {#s4}
==========

Our study is the first prospective cohort study on CHIKV long-term arthralgia that is based on the follow-up of patients who presented with acute CHIKV infection as the inclusion criterion. This study is also the first to define the evolution of CHIKV-induced arthralgia, mapping the frequency and location of arthralgic sites during a three year time period. We have also investigated the impact of CHIKV-chronic arthralgia on daily life of patients, identified clinical signs associated with arthralgia, and analyze biologic markers. Moreover we have evaluated associated risk factors and estimated the economic burden of this disease. Together, these data allow us to define the features of CHIKV-induced chronic arthralgia ([Table 5](#pntd-0002137-t005){ref-type="table"}), as compared to other viral arthritis [@pntd.0002137-Outhred1], and to establish a detailed understanding of the public health problem resulting from CHIKV-chronic arthralgia.

10.1371/journal.pntd.0002137.t005

###### Features of patients with chronic CHIKV-associated arthralgia.

![](pntd.0002137.t005){#pntd-0002137-t005-5}

  ---------------------- -------------------------------------------------
  Age                                          \>35
  Sex ratio (M/F)                               1/1
  Number of sites                     oligo or polyarthralgia
  Sites                            upper limbs : fingers. wrist
                                    lower limbs : knees. ankles
  Type                                      symmetrical
                                         permanent or not
                                             migratory
                                       highly incapacitating
                          morning stiffness duration average: ≈30 minutes
  General sign fever                         no fever
  Other clinical signs                         edema
                                         cutaneous lesion
                                              myalgia
                                    sleep and memory disorders
  Laboratory tests                          CRP normal
                                            ACCP normal
                                        antinuclear normal
                                     anti CHIKV IgGs positive
  Risk factor                                diabetes
  ---------------------- -------------------------------------------------

Our data reveal that more than 60% of CHIKV-infected patients suffer from arthralgia, 36 months after acute infection. This high percentage of patients with long-term symptoms was also reported by other studies of Italian cohorts and French cohorts of La Réunion Island or metropolitan France [@pntd.0002137-Borgherini1], [@pntd.0002137-Larrieu1], [@pntd.0002137-Sissoko1], [@pntd.0002137-Moro1], [@pntd.0002137-Couturier1] but is dramatically higher than documented in India and Senegal [@pntd.0002137-Brighton1], [@pntd.0002137-Chopra1], [@pntd.0002137-Mathew1], [@pntd.0002137-Kularatne1], [@pntd.0002137-deAndrade1]. While this discrepancy may result from particular features of the CHIKV strain responsible for the La Réunion outbreak, data from Italy following the 2007 outbreak resulted from a CHIKV strain more closely related to the viral strain present in India [@pntd.0002137-Rezza1], with more than 60% of CHIKV patients in Italy having reported myalgia, asthenia or arthralgia 12--13 months after the acute disease [@pntd.0002137-Moro1]. Alternatively, reported differences may be a result of different genetic backgrounds of these populations. As joint pain is considered a subjective symptom, it might also reflect a difference in pain threshold of patients or reporting from physicians, thus reflecting differences in health care practices.

Long-term CHIKV-associated arthralgia were mainly symmetrical, involving more than 2 different joints. Hand, wrist, ankle and knee were found to be the most affected, consistent with other studies [@pntd.0002137-Borgherini1], [@pntd.0002137-Larrieu1]. Moreover, 60--80% of patients had relapsing arthralgia, while 20--40% had unremitting arthralgia. While some patients reported "migrating" arthralgia, most disease symptoms mapped to joints that were most painful during acute Chikungunya disease. Thus, symptoms at the chronic phase may be indirectly associated to virus replication at the time of acute infection [@pntd.0002137-Couderc1], [@pntd.0002137-Labadie1], [@pntd.0002137-Gardner1].

In addition to arthralgia, many patients suffered from myalgia and cutaneous lesions and several cognitive dysfunctions. Although study patients did not display neurological symptoms at the acute phase of disease, we cannot exclude that cognitive dysfunctions result from CHIKV spread in the CNS, as it has been reported that CHIKV disseminates to the CNS in humans and in animal models [@pntd.0002137-Grivard1], [@pntd.0002137-Couderc1], [@pntd.0002137-Labadie1], [@pntd.0002137-Economopoulou1]. Similar to other studies, chronic arthralgia are considered incapacitating for daily life tasks and impacted professional activities and quality of life [@pntd.0002137-Moro1], [@pntd.0002137-Couturier1]. Beside this impact on patient, the economic burden of this long-term pathology is also very significant, independently of the cost of the acute disease [@pntd.0002137-Soumahoro1].

The longitudinal design of our study enabled us to identify risk factors for development of long-term arthralgia. Individuals over the age of 35 years or with diabetes were more likely to suffer from chronic arthralgia. The age has been reported to be a risk factor with some cohorts [@pntd.0002137-Couturier1], [@pntd.0002137-Soumahoro2], [@pntd.0002137-Hoarau1], but not in others [@pntd.0002137-Larrieu1], [@pntd.0002137-Chow1]. None of our available parameters to measure the severity of acute disease were associated with long-term arthralgia. This may be explained by differences in the way to measure disease severity in other studies [@pntd.0002137-Larrieu1]. Importantly, we show that the presence and intensity of arthralgia at M4 after the onset of the acute disease is a good predictor of long-term arthralgia.

Our study did not identify positive markers for autoimmune or rheumatoid arthritis. Additionally, we failed to identify systemic biomarkers associated with the arthralgic phenotype. Nevertheless, a slightly more elevated inflammatory status is found in a subset of arthralgic patients who have detectable serum level of IL1α, IL15 and slight elevation in Factor VII, C3 and CRP. This signature differs from that observed at the onset of the infection, when circulating virus is detectable and type I interferon, IP10, MCP1, ISG15 are highly elevated [@pntd.0002137-Werneke1], [@pntd.0002137-Schilte1], [@pntd.0002137-Her1]. Others have identified IL6 and GM-CSF or IL12 as being specifically associated with long-term arthralgia [@pntd.0002137-Hoarau1], [@pntd.0002137-Chow1]. However, these studies were performed much earlier in the chronic phase (2--3 months and one year after disease onset).

Our study shows that anti-CHIKV antibody titers were more elevated in ART+ patients than in ART- patients. This is in agreement with a recent study [@pntd.0002137-Gerardin2]. This higher level of antibodies could be associated with a more severe acute infection [@pntd.0002137-Gerardin2]. However, in our study, the level of antibody at M36 did not correlate with acute disease severity. Alternatively, this could reflect a persisting antigenic stimulation in ART+ patients (see below). Interestingly, it has been reported that viremia level at the acute phase correlates with a faster appearance of neutralizing antibodies and a better recovery 2--3 months after the acute phase [@pntd.0002137-Kam1].

Similarly to CHIKV, other so called "arthritogenic" alphaviruses, notably Ross River virus (RRV), are known to cause acute as well as chronic arthralgia [@pntd.0002137-Laine1]. Our data indicates that chronic symptoms are linked to the initial local joint inflammation and are not associated with markers of systemic inflammation or autoimmunity. A local inflammation of the joint could be maintained by the local persistence or delayed clearance of viral antigens. This is consistent with report of Hoarau *et al*. [@pntd.0002137-Hoarau1] who detected persistent CHIKV antigens within the synovial fluid of a patient suffering from chronic arthralgia. Moreover, experimental studies in CHIKV infected animal indicate that the joint is the most highly infected tissue, making it plausible that incomplete viral antigen clearance in this anatomical site may account for the long-term symptoms [@pntd.0002137-Couderc1]. RRV has been shown to persist *in vitro* in mouse macrophages, and a model of RRV chronic arthritis suggests that viral persistence may account for chronic disease [@pntd.0002137-Way1]. RRV and CHIKV have been shown to be weakly tropic for macrophages *in vitro* [@pntd.0002137-Sourisseau1], [@pntd.0002137-Linn1] but the presence of antibodies dramatically increased RRV entry into macrophage [@pntd.0002137-Linn1]. Further studies will be required to assess the role of macrophages, as well the role of persistent infection and antibodies in chronic arthritis caused by CHIKV.

In sum, this study furthers our understanding of the pathophysiology of CHIKV chronic arthralgia, a prerequisite for the development of efficient therapeutic strategies and for assessing the burden of disease inflicted upon populations affected by epidemic Chikungunya disease.
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